PCI Pharma Services is pouring $365 million to expand its US and Irish footprint for commercial and clinical packaging of drug-device products to meet “evolving” market needs.
The CDMO, which specializes in making drug devices like injectables and vials, is undergoing expansions at its site in Rockford, IL. In Ireland, it is building one facility and opening a recently acquired factory, according to a Tuesday release.
In Rockford, PCI Pharma is building a 545,000-square-foot expansion to add capacity for packaging injectable drugs. The expansion will include 345,000 square feet to manufacture prefilled syringes, autoinjectors and vials, and another 130,000 square feet for warehousing.
At the same site, the CDMO is also planning to expand by 70,000 square feet to add capacity for manufacturing “patient-centric drug devices” such as autoinjectors and on-body injectors. This expansion will begin operations in the third quarter of 2025.
Meanwhile, in Ireland, PCI Pharma said it is constructing a new factory at its campus north of Dublin, which is planned to start production in the third quarter of 2025. The new facility will label and package injectable and drug-device combination products, as well as house cold supply chains for biologics.
The CDMO will open the recently acquired commercial-scale factory near Dublin in the fourth quarter of this year, which will provide the company with temperature-controlled storage space. The facility can also manufacture injectables and oral solid dose products.
PCI Pharma has been busy expanding over the past few years, including a $100 million buildout of its facility in Bedford, NH, as well as an earlier $50 million investment at its Rockford facility as announced in March 2023.
The CDMO currently has a total of 14 facilities, seven of which are in the US, three in the UK, three others across Europe and one in Melbourne, Australia, according to its website.